Author:
Pelaia Corrado,Benfante Alida,Busceti Maria Teresa,Caiaffa Maria Filomena,Campisi Raffaele,Carpagnano Giovanna Elisiana,Crimi Nunzio,D’Amato Maria,Foschino Barbaro Maria Pia,Maglio Angelantonio,Minenna Elena,Nolasco Santi,Paglino Giuseppe,Papia Francesco,Pelaia Girolamo,Portacci Andrea,Ricciardi Luisa,Scichilone Nicola,Scioscia Giulia,Triggiani Massimo,Valenti Giuseppe,Vatrella Alessandro,Crimi Claudia
Abstract
BackgroundThe efficacy of dupilumab as biological treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit the pathophysiologic mechanisms involved in type 2 inflammation.ObjectiveTo assess in a large sample of subjects with severe asthma, the therapeutic impact of dupilumab in real-life, with regard to positive or negative skin prick test (SPT) and CRSwNP presence or absence.MethodsClinical, functional, and laboratory parameters were measured at baseline and 24 weeks after the first dupilumab administration. Moreover, a comparative evaluation was carried out in relation to the presence or absence of SPT positivity and CRSwNP.ResultsAmong the 127 recruited patients with severe asthma, 90 had positive SPT, while 78 reported CRSwNP. Compared with the 6 months preceding the first dupilumab injection, asthma exacerbations decreased from 4.0 (2.0-5.0) to 0.0 (0.0-0.0) (p < 0.0001), as well as the daily prednisone intake fell from 12.50 mg (0.00-25.00) to 0.00 mg (0.00-0.00) (p < 0.0001). In the same period, asthma control test (ACT) score increased from 14 (10-18) to 22 (20-24) (p < 0.0001), and sino-nasal outcome test (SNOT-22) score dropped from 55.84 ± 20.32 to 19.76 ± 12.76 (p < 0.0001). Moreover, we observed relevant increases in forced expiratory volume in one second (FEV1) from the baseline value of 2.13 L (1.62-2.81) to 2.39 L (1.89-3.06) (p < 0.0001). Fractional exhaled nitric oxide (FeNO) values decreased from 27.0 ppb (18.0-37.5) to 13.0 ppb (5.0-20.0) (p < 0.0001). These improvements were quite similar in subgroups of patients characterized by SPT negativity or positivity, and CRSwNP absence or presence. No statistically significant correlations were detected between serum IgE levels, baseline blood eosinophils or FeNO levels and dupilumab-induced changes, with the exception of FEV1 increase, which was shown to be positively correlated with FeNO values (r = 0.3147; p < 0.01).ConclusionOur results consolidate the strategic position of dupilumab in its role as an excellent therapeutic option currently available within the context of modern biological treatments of severe asthma and CRSwNP, frequently driven by type 2 airway inflammation.
Subject
Immunology,Immunology and Allergy
Reference48 articles.
1. Novel biological therapies for severe asthma endotypes;Pelaia;Biomedicines,2022
2. GINA report: Global strategy for asthma management and prevention2022
3. Dupilumab for the treatment of asthma;Pelaia;Expert Opin Biol Ther,2017
4. The role of dupilumab in severe asthma;Ricciardolo;Biomedicines,2021
5. Role of interleukin-13 in asthma;Corren;Curr Allergy Asthma Rep,2013
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献